In order to promote the construction and development of tumor immunotherapy in Sichuan and Hubei, and to improve the clinical scientific research level of physicians in Sichuan and Hubei, Chengdu High-tech Medical Association held the "New Advances in Sichuan and Hubei Lung Cancer Immunotherapy Exchange Conference" on September 17, 2021.

The meeting invited Professor Tao Wang from Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology to share "Clinical Dose Exploration of Immunization and Antivascular Drug Therapy"; Professor Zhao Jing from Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology focused on explaining To practice: Discussion on hot issues of immune-related adverse reaction management; Professor Zhang Mingsheng from Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology shared the "Analysis of Anti-tumor Mechanism of Subcutaneous Injection of PD-1 and New Progress in Clinical Research". The experts and professors at the meeting discussed the following issues:

1. Are there differences in efficacy and safety between PD-1/L1 antibodies?

2. After the PD-1 monoclonal antibody is resistant to clinical treatment, should you consider changing to PD-L1 monoclonal antibody to challenge or abandon the immunotherapy program?

3. Envolimab is the first subcutaneous injection of PD-L1 antibody, can its convenient and fast medication method bring clinical benefits? Which patients are the potential advantage groups for subcutaneous injection?

This conference provides a platform for clinical medical practitioners and scientific researchers to exchange diagnosis and treatment technologies and academic research results, which is conducive to promoting academic discussions and exchanges of classic cases and cutting-edge technologies in tumor immunity, and establishing comprehensive medical treatment and standardized treatment in oncology. Concept. It is of great significance to promote the development of high-quality clinical research in the field of medical oncology and promote the level of clinical scientific research.